ArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002
ArriVent dosed its first U.S. patient in the Phase 1 trial (NCT07755436) of ARR-002, a potential first-in-class MUC16/NaPi2b dual-target tetravalent ADC for advanced or metastatic ovarian and endometrial cancer. This is the company's second ADC to enter the clinic, broadening its pipeline beyond lung and gastrointestinal cancers. Dual targeting is designed to overcome heterogeneous target expression that limits single-target ADCs.
Key figures
- Drug Name
- ARR-002 (AV-P138-ADC)
- Phase Of Trial
- Phase 1
- Dar
- 4
- Trial id
- NCT07755436
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.